文献速递呼吸道感染呼吸危重症与机械通气

创新恒流罩降低COVID-19呼吸道治疗中医护感染风险

COVID-19: minimising risk to healthcare workers during aerosol-producing respiratory therapy using an innovative constant flow canopy.
PubMed 文献 · Eur Respir J · 2020-05-21

本文介绍一种创新恒流罩,用于COVID-19呼吸衰竭患者接受无创通气、持续气道正压或经鼻高流量氧疗时,可最大限度降低医护人员气溶胶暴露风险。文中指出无创呼吸支持可推迟或避免插管,但气溶胶生成是主要隐患,恒流罩为解决该问题提供了新思路。

要点

  • 无创通气、CPAP和HFNC可作为COVID-19呼吸衰竭一线治疗,推迟或避免插管。
  • 气溶胶生成是使用无创呼吸支持时医护人员感染的主要风险。
  • 恒流罩可在提供无创呼吸支持的同时最小化医护人员感染风险。

核心结论

  • 创新恒流罩使无创呼吸支持在COVID-19患者中应用时能将医护人员感染风险降至最低。

主要发现

  • 无创通气、持续气道正压和经鼻高流量氧疗可作为COVID-19呼吸衰竭患者的一线治疗,推迟并可能避免插管和有创机械通气。
  • 近期系统综述和荟萃分析表明,与常规氧疗相比,经鼻高流量氧疗减少插管需求,但死亡风险和ICU住院时间无变化。
  • 无直接证据支持使用无创通气,因其失败率较高;但当资源有限且无法进行有创通气时,使用无创通气可能是合理的。
  • 使用无创呼吸支持的主要隐患是产生含病毒小颗粒的气溶胶,可能悬浮于空气中,增加医护人员风险。
  • 气溶胶化风险取决于使用时长、流速、面罩漏气以及患者咳嗽和配合度等多种变量。

临床怎么用

  • 在COVID-19呼吸衰竭患者中可考虑使用恒流罩进行无创呼吸支持,以降低医护人员气溶胶暴露风险。
  • 资源有限无法进行有创通气时,使用无创通气可能是合理选择。
  • 使用无创呼吸支持时需关注使用时长、流速、面罩漏气和患者咳嗽配合度等影响气溶胶化的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An innovative constant flow canopy enables noninvasive respiratory support with minimal risk of healthcare worker infection https://bit.ly/3eqgoVZ Noninvasive ventilation (NIV), continuous positive airway pressure (CPAP) and high-flow nasal cannula (HFNC) can be used as the first line of treatment in coronavirus disease 2019 (COVID-19) patients with respiratory failure, postponing and maybe even avoiding the need for intubation and mechanical ventilation [1]. Recent systematic review and meta-analysis demonstrated that HFNC reduces the need for intubation compared with conventional oxygen, with no change in the death risk or length of stay in the intensive care unit [2, 3]. No direct evidence supports the use of NIV, due to a high failure rate [4]. However, when resources become limited, with no option of invasive ventilation, the use of NIV may be justified. The major caveat of using noninvasive respiratory support in the face of the COVID-19 pandemic is the generation of aerosols, composed of small virus-containing particles, which may remain suspended in the air, with increased risk for healthcare workers [5, 6]. The risk of aerosolisation depends on many variables, including duration of use, flow velocity, mask leakage and patient coughing and cooperation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Adir Y, Segol O, Kompaniets D, et al. COVID-19: minimising risk to healthcare workers during aerosol-producing respiratory therapy using an innovative constant flow canopy. Eur Respir J. 2020. PMID: 32312865. doi:10.1183/13993003.01017-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。